SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its first quarter financial results on May 5, 2016 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day to provide a summary of its financial results and general business updates. A replay of the call will be available for one week following the event.
To access the conference call via the Internet, go to www.XenoPort.com. Please join the call at least 15 minutes prior to the start to ensure time for any software downloads that may be required.
To access the live conference call via phone, dial 1-888-275-3514. International callers may access the live call by dialing 706-679-1417. The reference number to enter the call is 77273079.
The replay of the conference call may be accessed that same day after 8:00 p.m. Eastern Time, via the Internet, at www.XenoPort.com, or via phone at 1-855-859-2056 for domestic callers, or 404-537-3406 for international callers. The reference number to enter the replay of the call is 77273079.
XenoPort, Inc. is a biopharmaceutical company focused on commercializing HORIZANT® (gabapentin enacarbil) Extended-Release Tablets in the United States. XenoPort has entered into an agreement with the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under which the NIAAA has initiated a clinical trial evaluating gabapentin enacarbil as a potential treatment for patients with alcohol use disorder. REGNITE® (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. XenoPort has granted exclusive world-wide rights for the development and commercialization of its clinical-stage oral product candidate, arbaclofen placarbil, to Indivior UK Ltd. for all indications. Pending review by the U.S. Government under the Hart-Scott-Rodino Antitrust Improvements Act, XenoPort has also granted U.S. rights for the development and commercialization of its clinical-stage oral product candidate, XP23829, to Dr. Reddy’s Laboratories. XenoPort developed and owns exclusive worldwide rights to XP21279, a prodrug of levodopa that is a potential treatment for patients with idiopathic Parkinson's disease.
HORIZANT, REGNITE and XENOPORT are registered trademarks of XenoPort, Inc.